about
TGF-β2 suppresses macrophage cytokine production and mucosal inflammatory responses in the developing intestineBiomarkers, Early Diagnosis, and Clinical Predictors of Bronchopulmonary DysplasiaNano-TiO₂ particles impair adhesion of airway epithelial cells to fibronectinAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates: Design of a Retrospective Cohort StudyPharmacokinetics, microbial response, and pulmonary outcomes of multidose intravenous azithromycin in preterm infants at risk for Ureaplasma respiratory colonization.Early CPAP versus surfactant in extremely preterm infants.Target ranges of oxygen saturation in extremely preterm infants.Outcome of term infants using apgar scores at 10 minutes following hypoxic-ischemic encephalopathy.Neurodevelopmental impairment following neonatal hyperoxia in the mouse.Effect of cigarette smoke extract on neonatal porcine vascular smooth muscle cells.Nitric oxide administration using an oxygen hood: a pilot trial.Pulmonary matrix metalloproteinase-9 activity in mechanically ventilated children with respiratory syncytial virus.Pathogenetics of alveolar capillary dysplasia with misalignment of pulmonary veinsCytokines associated with bronchopulmonary dysplasia or death in extremely low birth weight infants.Impact of timing of birth and resident duty-hour restrictions on outcomes for small preterm infants.Outcomes of extremely preterm infants following severe intracranial hemorrhage.Predicting time to hospital discharge for extremely preterm infantsIntestinal microbiota of preterm infants differ over time and between hospitalsABO blood group is associated with response to inhaled nitric oxide in neonates with respiratory failure.Intercenter differences in bronchopulmonary dysplasia or death among very low birth weight infants.Prolonged duration of initial empirical antibiotic treatment is associated with increased rates of necrotizing enterocolitis and death for extremely low birth weight infants.Outcomes of extremely low birthweight infants with acidosis at birth.Myofibroblast differentiation and enhanced TGF-B signaling in cystic fibrosis lung disease.Peptide-directed highly selective targeting of pulmonary arterial hypertension.Hypoxia-induced inhibition of lung development is attenuated by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone.PaCO2 in surfactant, positive pressure, and oxygenation randomised trial (SUPPORT).Prediction of bronchopulmonary dysplasia by postnatal age in extremely premature infantsIntegrated genomic analyses in bronchopulmonary dysplasia.Baseline values of candidate urine acute kidney injury biomarkers vary by gestational age in premature infantsIdentification of extremely premature infants at high risk of rehospitalization.Cytokines and neurodevelopmental outcomes in extremely low birth weight infantsInhaled PGE1 in neonates with hypoxemic respiratory failure: two pilot feasibility randomized clinical trialsHypoxia induces downregulation of PPAR-γ in isolated pulmonary arterial smooth muscle cells and in rat lung via transforming growth factor-β signaling.Genetic polymorphisms of heme-oxygenase 1 (HO-1) may impact on acute kidney injury, bronchopulmonary dysplasia, and mortality in premature infants.Center Variation in Intestinal Microbiota Prior to Late-Onset Sepsis in Preterm Infants.Hyperoxia-induced neonatal rat lung injury involves activation of TGF-{beta} and Wnt signaling and is protected by rosiglitazoneSetting research priorities to improve global newborn health and prevent stillbirths by 2025.Prospective analysis of pulmonary hypertension in extremely low birth weight infants.Early exposure to hyperoxia or hypoxia adversely impacts cardiopulmonary developmentIn vitro studies on the effect of particle size on macrophage responses to nanodiamond wear debris.
P50
Q24301263-23636B53-5046-4757-B748-B12B0A2D973CQ28081434-3397C4AD-BA57-4F09-A90E-EB479A7BD574Q28384461-6FAC2132-11E2-4974-AC94-D9019E51ADEFQ30276211-B4AC8600-4553-45A9-8B1E-D052CB7E13B8Q30301367-A91FBC00-CE64-44C2-A577-517B638BF61AQ30432764-546CC663-120E-4190-8DA1-9209A227148AQ30434084-5D2585D4-886B-404B-8004-4E711813E157Q30437082-B7010036-10D5-4F4C-9034-DA71030277E0Q30573333-D6A6C777-539B-4410-AECD-6DB833FE1651Q31856932-FE9B4533-4503-40CC-AE70-0ADF49EF93DFQ33404578-6E1DE4D9-6C24-4028-9DBA-E946646A8B97Q33762362-F25B207D-0FC9-41BE-9923-595F9D6C28D6Q33919970-CABECF80-DAC1-4263-9682-BE5CEEDD31A4Q33990311-DD0A8F94-BA3B-43F5-B4EC-DB46DD2ACB44Q34074726-B738E421-5131-42F0-8F0A-DA58E1417EE5Q34083663-D17EA423-A9EB-4694-9BAA-C4E26642DB9EQ34183129-6548F558-A988-4446-A9BE-EB47D707C77FQ34372788-90EABEB9-31EC-4201-8CC7-AAF2B1B74250Q34416421-9B74E91A-E432-4986-B700-7DA4D4B34F8AQ34439791-E2C08F24-AD5F-4548-B502-01D2D08797D1Q34602603-05A6E556-3043-4012-BD8D-F5E7E6BBE009Q34761426-CC92348C-5139-4247-8CB1-60F3B0C3DECEQ34946558-0ED0CAA3-CA7E-45A6-A806-0847ECE8C8A9Q35070520-341D6FE1-403E-4584-BAC8-5D21556943FAQ35087009-A2AFBC9E-2872-41CA-988C-650D1C1590E3Q35106926-FFBA0748-2CF0-451F-ADCC-0BDC173C654BQ35107249-8720BB5A-BC77-48BE-93B1-36B98624D08EQ35132451-B53A596F-2857-466E-9C8A-CDFF157ACB24Q35154205-CBE9BD8A-86F9-4294-838C-0F3752E52620Q35530027-76E1CEB8-0D5F-4F7F-915D-3E546D0D8F93Q35549099-26AAEE1E-F336-4D81-921D-9AC194F0AEB3Q35552825-A15B6001-B44D-43D1-B709-5E97CE24F651Q35601455-CC9F34A6-36E8-4759-95AE-D51AC9AA27E5Q35629912-E898A878-5C64-4AFF-AD61-97EB31080144Q35674518-A9EAA565-BA86-4251-8A3D-90F6B26D662CQ35776531-6B71C74D-7538-47F8-82F9-3553402CB3D3Q35786265-B049FF45-FE61-48FD-BA43-ECB2093ED15BQ35787835-1A6BB1F8-16D1-454B-95FB-5A2F815BA950Q35816440-5A63F26D-A6A2-4B68-A6BB-65A0D506837FQ35856937-81F158CA-0687-4950-84CE-8392764F7FAA
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Namasivayam Ambalavanan
@ast
Namasivayam Ambalavanan
@en
Namasivayam Ambalavanan
@es
Namasivayam Ambalavanan
@nl
Namasivayam Ambalavanan
@sl
type
label
Namasivayam Ambalavanan
@ast
Namasivayam Ambalavanan
@en
Namasivayam Ambalavanan
@es
Namasivayam Ambalavanan
@nl
Namasivayam Ambalavanan
@sl
prefLabel
Namasivayam Ambalavanan
@ast
Namasivayam Ambalavanan
@en
Namasivayam Ambalavanan
@es
Namasivayam Ambalavanan
@nl
Namasivayam Ambalavanan
@sl
P106
P1153
6701406113
P21
P31
P496
0000-0003-0731-9092